Recommend upfront consolidation with high-dose melphalan and autologous stem cell support Journal Article

  


Authors: Shah, G. L.; Giralt, S. A.
Article Title: Recommend upfront consolidation with high-dose melphalan and autologous stem cell support
Abstract: The overall goal of treatment for multiple myeloma (MM) is to prolong survival for as long as possible with the minimal treatment burden for each patient. Consolidation with upfront high-dose melphalan and autologous hematopoietic stem cell transplantation (ASCT) can prolong progression-free and overall survival by deepening response. It thereby can improve quality of life by allowing patients to have a time on maintenance therapy along with infrequent office visits, making it cost-effective in many situations. The impact of minimal residual disease (MRD) negativity is important, but further studies are needed to quantify the pharmacoeconomic and quality-of-life differences between early and delayed transplant strategies. Therefore, with the currently available evidence, upfront ASCT is standard of care regardless of MRD status. © 2016 Elsevier Inc.
Keywords: multiple myeloma; minimal residual disease; autologous stem cell transplant
Journal Title: Seminars in Oncology
Volume: 43
Issue: 6
ISSN: 0093-7754
Publisher: Elsevier Inc.  
Date Published: 2016-12-01
Start Page: 707
End Page: 708
Language: English
DOI: 10.1053/j.seminoncol.2016.11.007
PROVIDER: scopus
PUBMED: 28061992
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85007553503&doi=10.1053%2fj.seminoncol.2016.11.007&partnerID=40&md5=07485cb11cd613ac6165c54432f87345
Notes: Review -- Export Date: 2 February 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Sergio Andres Giralt
    1050 Giralt
  2. Gunjan Lalitchandra Shah
    418 Shah
Related MSK Work